1194057-63-0

Usage

Uses

Used in Pharmaceutical Industry:
(2S,4R)-4-BenzyloxycarbonylaMino-2-hydroxyMethyl-pyrrolidine-1-carboxylic acid tert-butyl ester is used as a building block for the synthesis of various pharmaceutical compounds. Its unique structure and chiral properties make it a versatile component in the development of new drugs and medications.
Used in Asymmetric Synthesis:
(2S,4R)-4-BenzyloxycarbonylaMino-2-hydroxyMethyl-pyrrolidine-1-carboxylic acid tert-butyl ester is used as a chiral auxiliary in asymmetric synthesis. Its specific stereochemistry aids in the selective formation of desired enantiomers, which is crucial for the production of biologically active compounds with minimal side effects.
It is important to handle (2S,4R)-4-BenzyloxycarbonylaMino-2-hydroxyMethyl-pyrrolidine-1-carboxylic acid tert-butyl ester with care and follow proper safety protocols to minimize health risks associated with its use.

Upstream product

• 1279038-50-4 (2S,4R)-tert-butyl 4-amino-2-(hydroxymethyl)pyrrolidine-1-carboxylate hydrochloride 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 1460307-57-6 C₃₈H₄₇N₃O₈ 
• 1194057-65-2 ethyl 7-((2S,4R)-4-benzyloxycarbonylamino-2-(hydroxymethyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-hydroxymethyl-4-oxo-1,4-dihydroquinoline-3-carboxylate 
• 1194057-67-4 ethyl (3aS,5R)-5-benzyloxycarbonylamino-13-cyclopropyl-8-fluoro-10-oxo-3a,4,5,6,10,13-hexahydro-1H,3H-pyrrolo[2',1':3,4][1,4]oxazepino[5,6-h]quinoline-11-carboxylate 
• 1194057-64-1 ethyl 7-((2S,4R)-4-benzyloxycarbonylamino-2-(hydroxymethyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-fomyl-4-oxo-1,4-dihydroquinoline-3-carboxylate 
• 1460305-27-4 benzyl N-[(15R,16aS)-10-methyl-9,12-dioxo-9,10,11,12,15,16,16a,17-octahydro-14H-dibenzo[i,k ]pyrrolo[2,1-c][1,4,7]oxadiazacyclododecin-15-yl]carbamate 
• 1460303-63-2 C₂₄H₂₉IN₂O₅ 
• 1194057-62-9 benzyl ((3R,5S)-5-(hydroxymethyl)pyrrolidin-3-yl)carbamate hydrochloride 

Relevant academic research and scientific papers

CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS

The conformationally restricted, spatially defined macrocyclic ring system of formula (I) is constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. Macrocycles described by this ring system I are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase. They are designed to interact with a variety of specific biological target classes, examples being agonistic or antagonistic activity on G-protein coupled receptors (GPCRs), inhibitory activity on enzymes or antimicrobial activity. In particular, these macrocycles show inhibitory activity on endothelin converting enzyme of subtype 1 (ECE-1 ) and/or the cysteine protease cathepsin S (CatS), and/or act as antagonists of the oxytocin (OT) receptor, thyrotropin-releasing hormone (TRH) receptor and/or leukotriene B4 (LTB4) receptor, and/or as agonists of the bombesin 3 (BB3) receptor, and/or show antimicrobial activity against at least one bacterial strain. Thus they are showing great potential as medicaments for a variety of diseases.